Trifecta Capital Advisors’s GSK GSK Stock Holding History

Trifecta Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.35K	Buy	+64	New	+$3.38K	﹤0.01%	278

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Trifecta Capital Advisors's GSK Position: Q2 2026 in Review

Trifecta Capital Advisors opened a new position in GSK (GSK) in Q2 2026: 64 shares worth $3.35K. The stake represents ﹤0.01% of the portfolio and ranks #278 among its holdings.

1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Trifecta Capital Advisors held 64 shares of GSK worth $3.35K as of Q2 2026.
GSK was a new Trifecta Capital Advisors position in Q2 2026.
GSK made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #278 holding.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.